Company profile: Fluent Biosciences
1.1 - Company Overview
Company description
- Provider of single-cell molecular analysis solutions without complex microfluidic instrumentation via its PIPseq Pre-Templated Instant Partitions platform for instantaneous self-assembly. Offers 3’ Single Cell RNA Kits (T2, T20, T100) for profiling up to 100,000 cells, a nuclei isolation kit, unique dual index kits for Illumina NGS instruments, and supplemental enrichment/amplification kits.
Products and services
- PIPseq T100 3’ Single Cell RNA Kit v4.0PLUS: Profiles up to 100,000 per reaction using 3’ RNA capture, with reagents for cell capture and library preparation in a high-throughput kit
- PIPseq T20 3’ Single Cell RNA Kit v4.0PLUS: Enables up to 20,000 cells per sample with 3’ RNA capture, includes cell capture and library preparation reagents, Illumina-compatible for NGS instruments
- PIPseq T2 3’ Single Cell RNA Kit v4.0PLUS: Profiles up to 2,000 cells per reaction with 3’ RNA capture, includes reagents for cell capture and library preparation in reaction-scale kit
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fluent Biosciences
Candel Therapeutics
HQ: United States
Website
- Description: Provider of viral cancer immunotherapies and a discovery platform. Offers CAN-2409, a genetically modified adenovirus to elicit individualized anti-tumor responses in prostate, pancreatic, and lung cancers; CAN-3110, a modified herpes simplex virus for recurrent high-grade glioma; enLIGHTEN Discovery Platform to create HSV-based viral immunotherapies for solid tumors; conducts clinical trials for prostate, brain, pancreatic, and lung cancers and provides an expanded access policy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Candel Therapeutics company profile →
Genomic Vision
HQ: France
Website
- Description: Provider of novel genetic tests and research tools for life sciences, developed and commercialized using Molecular Combing, a proprietary single DNA molecule detection technology, combined with biomarker discovery; focused on DNA analysis and genetic testing in cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomic Vision company profile →
Swift Biosciences
HQ: United States
Website
- Description: Provider of molecular biology reagents for research and diagnostic applications; based in Ann Arbor, Michigan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Swift Biosciences company profile →
Select Immunogenomics
HQ: United States
Website
- Description: Provider of data analysis, predictive modeling, and reporting in support of genomic studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Select Immunogenomics company profile →
Devyser
HQ: Sweden
Website
- Description: Provider of diagnostic kits for complex DNA testing in oncology, hereditary diseases, and transplantation, used to guide targeted cancer therapies and enable genetic testing. Sold in 60+ countries, offerings include NGS-based tests for thalassemia, cystic fibrosis, familial hypercholesterolemia, thrombophilia, HFE mutations, and Y-chromosome microdeletions linked to male infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Devyser company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fluent Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fluent Biosciences
2.2 - Growth funds investing in similar companies to Fluent Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fluent Biosciences
4.2 - Public trading comparable groups for Fluent Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →